中国医院用药评价与分析2025，Vol.25Issue(2)：165-171,175,8.DOI:10.14009/j.issn.1672-2124.2025.02.009
国家中药复方专利内治卵巢囊肿的用药规律与作用机制研究
Medication Rules and Mechanism of Internal Therapy of Traditional Chinese Medicine Compound Patents in the Treatment of Ovarian Cysts
摘要
Abstract
ABSTRACT OBJECTIVE:Based on the patent database of the China National Intellectual Property Administration,to systematically analyze the medication rules and mechanism of internal therapy of traditional Chinese medicine compound patents in the treatment of ovarian cysts(OC),so as to validate the relevant results through cell experiments.METHODS:The patent literature was screened to construct the data set of traditional Chinese medicine compound patents and obtain the core drugs after analysis.The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and GeneCards database were used to obtain active components and targets,STRING and UniProt were used to conduct standardized processing.Veeny was used to obtain intersecting targets,Cytoscape was used to draw the network,STRING was used to obtain protein-protein interaction network,Metascape was used to conduct enrichment analysis,AutoDockTools was used to conduct molecular docking,CCK-8 method was used to measure the cell viability and Western blotting was used to measure protein expression quantity.RESULTS:(1)A total of 104 patent studies including 104 formulas and 351 traditional Chinese medicine were enrolled,so that Sparganii rhizoma,Curcumae rhizoma,Angelicae sinensis radix,and Persicae semen were identified as the core drugs.(2)A total of 38 intersecting targets for the treatment of OC were screened out,the key active components included formononetin,β-sitosterol and stigmasterol.The core targets were PTGS2,CASP3 and PPARG.Biological processes,molecular functions and cellular components such as hormone response,organelle outer membrane and protein structural domain-specific binding were obtained from the Gene Ontology functional enrichment analysis.Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that interleukin 17 and advanced glycosylation end product(AGE)-AGE receptor were the major signaling pathways.Molecular docking indicated stable binding between active ingredient and target protein.(3)Formononetin showed no toxicity to KGN cells at the concentration of 20 μmol/L to 80 μmol/L,while the cell survival rate decreased at the concentration of 100 μmol/L.Compared with the model group(5 μg/mL of LPS,incubated for 12 h),the protein expression of PTGS2 and CASP3 reduced significantly(P<0.05)in the formononetin group(low,medium and high dose groups),and the expression of PPARG increased in the formononetin high-dose group(P<0.05),with statistically significant differences.CONCLUSIONS:Data mining analysis reveals that the internal therapy of most traditional Chinese medicine compound patents for the treatment of OC are drugs of blood-activating and Qi-promoting,stasis-eliminating and stagnation-removing,and the key active components including formononetin,β-sitosterol and stigmasterol mainly acts on the core targets such as PTGS2,CASP3 and PPARG.Formononetin shows no obvious toxicity to KGN cells at the concentration of 20 μmol/L to 80 μmol/L.Formononetin can effectively control the protein expression of PTGS2,CASP3 and PPARG in KGN cells to fulfill the efficacy of OC treatment.关键词
卵巢囊肿/中药复方专利/数据挖掘/网络药理学/分子对接/刺芒柄花素/人卵巢颗粒细胞Key words
Ovarian cysts/Traditional Chinese medicine compound patents/Data mining/Network pharmacology/Molecular docking/Formononetin/Human ovarian granulosa cells分类
药学引用本文复制引用
张凯民,刘瑾,萧绮俐,郭桢玉,邓嘉颖,周慧萍,周子添,王君玉,黄江鑫,凌静..国家中药复方专利内治卵巢囊肿的用药规律与作用机制研究[J].中国医院用药评价与分析,2025,25(2):165-171,175,8.基金项目
广东省中医药局科研项目(No.20212197) （No.20212197）
深圳市"医疗卫生三名工程"项目资助(No.SZZYSM202211006) （No.SZZYSM202211006）
